134 related articles for article (PubMed ID: 36368709)
1. Systematic mapping review of guidelines for
Hughes BN; Jorgensen KA; Cummings S; Morah D; Krause K; Rauh-Hain JA; Herzog TJ
Int J Gynecol Cancer; 2023 Feb; 33(2):250-256. PubMed ID: 36368709
[TBL] [Abstract][Full Text] [Related]
2. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
4. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA; Norquist B; Lacchetti C; Armstrong D; Grisham RN; Goodfellow PJ; Kohn EC; Levine DA; Liu JF; Lu KH; Sparacio D; Annunziata CM
J Clin Oncol; 2020 Apr; 38(11):1222-1245. PubMed ID: 31986064
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
Levy DE; Garber JE; Shields AE
J Gen Intern Med; 2009 Jul; 24(7):822-8. PubMed ID: 19455369
[TBL] [Abstract][Full Text] [Related]
6. High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control.
Laarabi FZ; Ratbi I; Elalaoui SC; Mezzouar L; Doubaj Y; Bouguenouch L; Ouldim K; Benjaafar N; Sefiani A
BMC Res Notes; 2017 Jun; 10(1):188. PubMed ID: 28577564
[TBL] [Abstract][Full Text] [Related]
7. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
9. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
10. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
12.
Talwar V; Rauthan A
Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Hall MJ; Reid JE; Wenstrup RJ
Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
Ingham SL; Warwick J; Buchan I; Sahin S; O'Hara C; Moran A; Howell A; Evans DG
J Med Genet; 2013 Jun; 50(6):368-72. PubMed ID: 23539753
[TBL] [Abstract][Full Text] [Related]
15. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
[TBL] [Abstract][Full Text] [Related]
17. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
